HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spiller, H. A. Articles by Sawyer, T. S. Search for Related Content PubMed PubMed Citation Articles by Spiller, H. A. Articles by Sawyer, T. S.

HENRY A. SPILLER, M.S., DABAT, is Director, Kentucky Regional Poison Center, Louisville. TAMA S. SAWYER, PHARM.D., CSPI, is Senior Administrative Specialist, Mid-America Poison Control Center, University of Kansas Hospital, Kansas City.

Address correspondence to Mr. Spiller at the Kentucky Regional Poison Center, P.O. Box 35070, Louisville, KY 40232-5070 (henry.spiller{at}nortonhealthcare.org).

Purpose. The toxicology of oral antidiabetic agents is reviewed. Summary. Type 2 diabetes mellitus is increasing to near epidemic proportions, with a reported 190 million patients worldwide. Use of oral antidiabetic medications is increasing along with a proportional increase in adverse events. Oral antidiabetic medications can be separated by mechanism of action into two groups: hypoglycemics (sulfonylureas and meglitinides) and antihyperglycemics (biguanides and -glucosidase inhibitors). The hypoglycemic agents pose a significant risk of morbidity, mortality, and permanent sequelae secondary to prolonged periods of hypoglycemia. However, outcomes are routinely good if intervention is initiated early, with the primary goal return of euglycemia using supplemental dextrose infusion and octreotide to reduce further insulin secretion. Metformin-associated lactic acidosis (MALA) can occur with both acute and chronic metformin exposure. While MALA is not common, its associated rates of morbidity and mortality can be high. Secondary to MALA, the patient may experience changes in the central nervous system, cardiovascular collapse, renal failure, and death. The primary goals of therapy are restoration of acid–base status and removal of metformin, using hemodialysis and bicarbonate therapy. There is no specific antidote for MALA. The -glucosidase inhibitors and thiazolidinediones pose minimal risk of adverse events in acute overdose. However, acarbose and all thiazolidinediones have been reported to produce hepatic injury with chronic therapy. Cessation of therapy with the offending agent and supportive care are the mainstays of overdose management with these drugs. Conclusion. The toxicity of oral antidiabetic agents differs widely in clinical manifestations, severity, and treatment. Index terms: Acarbose; Acidosis; Alkalinizing agents; Alpha-glucosidase inhibitors; Antidiabetic agents; Biguanides; Caloric agents; Dextrose; Diabetes mellitus; Dialysis; Dosage; Dosage schedules; Gastrointestinal drugs; Mechanism of action; Meglitinides; Metformin; Mortality; Octreotide; Sodium bicarbonate; Sulfonylureas; Thiazolidinediones; Toxicity

 

This article has been cited by other articles:

				M. Forrester Adult metformin ingestions reported to Texas poison control centers, 2000-2006 Human and Experimental Toxicology, July 1, 2008; 27(7): 575 - 583. [Abstract] [PDF]

				D. S Feig, G. G Briggs, and G. Koren Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? Ann. Pharmacother., July 1, 2007; 41(7): 1174 - 1180. [Abstract] [Full Text] [PDF]